Tredegar Corp. Q1 2002 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002. Tredegar Corporation operates primarily in Film Products, Aluminum Extrusions, and Biotechnology (Molecumetics and Therics), alongside a significant portfolio of venture capital investments. On March 22, 2002, management announced an intention to divest its biotech operations to focus on plastics and aluminum manufacturing, with completion expected by the end of 2002.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $174.2 million | $191.8 million |
| Net Income | $0.6 million ($0.02/share) | $1.9 million ($0.05/share) |
| Gross Profit Margin | 21.1% | 18.2% |
| Operating Cash Flow | $13.3 million | $14.4 million |
| Total Debt | $264.3 million | $265.0 million |
| Cash and Equivalents | $99.3 million | $46.1 million |
| Venture Capital NAV | $166.6 million | $296.5 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 9.2% year-over-year. Film Products sales fell 8.2% due to raw material price declines, while Aluminum Extrusions sales dropped 9.4% due to lower volume and prices.
- Profitability: Net income declined 69% to $583,000. This was driven by a $7.2 million after-tax loss from venture capital investments (compared to $5.3 million in 2001) and $637,000 in after-tax unusual charges for plant shutdowns.
- Accounting Changes: The company adopted new FASB standards effective Jan 1, 2002, eliminating goodwill amortization. This provided a positive impact of $750,000 after-tax to Q1 2002 results.
- Biotech Losses: The biotech segment reported an operating loss of $7.2 million, up from $4.1 million in Q1 2001, due to increased R&D spending and lower revenues.
- Interest Expense: Interest expense dropped to $2.2 million from $4.0 million, reflecting lower average interest rates (3.6% vs 6.7%) despite similar debt levels.
Outlook, Risks, and Unusual Items
- Divestiture Strategy: Management plans to complete the sale of Molecumetics and Therics by year-end 2002. Assets held for sale are valued at $15.5 million.
- Venture Capital Volatility: The Net Asset Value (NAV) of venture capital investments decreased by $14.2 million after-tax in the quarter. Significant depreciation was attributed to lower valuations in private companies (e.g., Appliant, MedManage) and public stock price declines (e.g., Illumina, Universal Access).
- Unusual Items: Q1 2002 included $1.0 million in pre-tax charges related to the shutdown of a Film Products plant in Pennsylvania and an Aluminum Extrusions plant in Texas.
- Liquidity: On April 30, 2002, the company replaced a maturing $275 million revolver with a new $100 million 364-day facility. The debt-to-capitalization ratio was 36% at quarter-end, well below the 50% covenant limit.
- Market Risks: The company faces exposure to resin and aluminum price volatility, foreign currency fluctuations (primarily Euro), and the inherent risks of early-stage technology investments.
Investor Verification Checklist
- Verify the timeline and terms of the pending divestiture of Molecumetics and Therics.
- Monitor the valuation trends of the venture capital portfolio, specifically the $14.2 million quarterly NAV decline.
- Assess the impact of raw material price fluctuations on Film Products and Aluminum Extrusions margins.
- Review the status of the new $100 million credit facility and future refinancing plans post-divestiture.
- Confirm the extent of cost savings realized from the announced plant shutdowns in Pennsylvania and Texas.